Biotech entity
All 4 tracked stories fall under one category: pharma. Morgan Stanley is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 4 tracked stories fall under one category: pharma. Morgan Stanley is the most frequent co-covered peer, appearing in 3 of the 4 tracked stories. Source depth averages 2 original sources per story, versus 3.5 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 6.1 for that window. That works out to roughly 0.2 stories per week across a 179-day span. This profile follows 4 Biotech stories mentioning Royal Bank of Canada across the period from February 27, 2026 to August 24, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 664 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Royal Bank of Canada. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgrades both stocks to Hold
Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
Enveric reports quarterly loss
Enveric Biosciences reported EPS of -$0.76 for the quarter.
RBC raises CTNM target to $23
Royal Bank of Canada raised its Contineum target from $22.00 to $23.00 with an Outperform rating.
Contineum reports Q2 results
Contineum reported Q2 EPS of -$0.40, beating consensus by $0.05.
Weiss Ratings reiterates Sell ratings
Weiss Ratings restated a Sell (d-) on CTNM and a Sell (e+) on ENVB.
Clinical Catalyst
Anticipated data readouts for sevasemten in Becker Muscular Dystrophy trials.
Morgan Stanley raises CTNM target
Morgan Stanley raised its price target on Contineum Therapeutics from $14.00 to $16.00 with an Equal Weight rating.
52-Week High
EWTX stock reaches a new yearly peak amid clinical pipeline optimism.
Analyst Upgrade
Wall Street Zen raises Edgewise Therapeutics to a 'Hold' rating.
A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.
Source: tickerreport.com · dailypolitical.com
Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Source: Ticker Report · Watch List News
Edgewise Therapeutics (NASDAQ: EWTX) has reached a new 52-week high, reflecting growing investor confidence in its clinical-stage pipeline for rare muscle and cardiac diseases. The surge follows recent analyst upgrades and positive sentiment surrounding its lead candidates, sevasemten and EDG-7500.
Source: dailypolitical.com · tickerreport.com
Royal Bank of Canada is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
